491 completed, 57 terminated, 41 withdrawn, 35 recruiting. 679 Phase 2, 51 Phase 1, 49 Phase 3.
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function | Phase 2 | Not yet recruiting | Foresee Pharmaceuticals Co., Ltd. | 135 | 2027-03-01 | 2026-07-20 |
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma | Phase 2 | Not yet recruiting | Indiana University | 30 | 2027-01-01 | 2026-02-27 |
| Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma | Phase 2 | Not yet recruiting | Sultan Qaboos University | 60 | 2027-01-01 | 2026-07-27 |
| Ginger's Therapeutic Potential in Asthma Ginger Extract, Placebo - Asthma | Phase 2 | Not yet recruiting | Emily DiMango, MD | 32 | 2026-11-01 | 2026-08-28 |
| A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma JNJ-95597528, Placebo - Asthma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 440 | 2026-10-05 | 2026-11-03 |
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-11-04 |
| Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma Dexamethasone (0.6mg/kg; Max 16mg) Once Daily, Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours, Methylprednisolone - Asthma (Diagnosis) | Phase 2 | Recruiting | Johns Hopkins All Children's Hospital | 159 | 2026-08-01 | 2026-08-12 |
| A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma Frevecitinib, Placebo - Severe Asthma | Phase 2 | Recruiting | Kinaset Therapeutics Inc | 512 | 2026-07-16 | 2026-07-28 |
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study KT-621 - Asthma (Diagnosis) | Phase 2 | Recruiting | Kymera Therapeutics, Inc. | 264 | 2026-06-25 | 2026-10-07 |
| Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare, Placebo nebulization (5 mL normal saline) plus standard asthma care - Asthma Acute, Asthma Attack | Phase 2 | Recruiting | Oman Medical Speciality Board | 100 | 2026-05-30 | 2026-10-19 |
| Efficacy of L-menthol on Breathlessness in Asthma L-menthol, Placebo - Asthma | Phase 2 | Recruiting | Region Skane | 20 | 2026-05-07 | 2026-08-19 |
| A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma GP MDI, BFF MDI, Placebo MDI - Asthma | Phase 2 | Recruiting | AstraZeneca | 69 | 2026-04-14 | 2026-10-13 |
| Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma ARO-RAGE, Placebo - Asthma | Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 36 | 2026-03-30 | 2026-10-01 |
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma AK139, Placebo - Asthma | Phase 2 | Not yet recruiting | Akeso | 160 | 2026-02-28 | 2026-02-27 |
| ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults ENV-294, Placebo - Asthma | Phase 2 | Recruiting | Enveda Therapeutics | 50 | 2026-01-09 | 2026-09-24 |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, CHF718 pMDI with HFA-134a - Asthma | Phase 2 | Recruiting | Chiesi Farmaceutici S.p.A. | 780 | 2025-12-17 | 2026-06-25 |
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| A Clinical Trial of Soluble Fiber for Asthma Inulin - Asthma in Children | Phase 2 | Recruiting | Phoenix Children's Hospital | 105 | 2025-11-10 | 2026-03-04 |
Showing 20 of 679. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (30) · Hypersensitivity (28) · Respiratory Sounds (16) · Rhinitis, Allergic (16) · Obesity (15) · Lung Diseases (13) · Respiratory Tract Diseases (12) · Dyspnea (11) · Inflammation (11) · Rhinitis (11) · Bronchial Diseases (9) · Status Asthmaticus (9) · Respiratory Hypersensitivity (8) · Lung Diseases, Obstructive (7)
Immune System Diseases (677) · Hypersensitivity, Immediate (675) · Respiratory Hypersensitivity (671) · Bronchial Diseases (670) · Respiratory Tract Diseases (667) · Lung Diseases, Obstructive (663) · Lung Diseases (657) · Hypersensitivity (651) · Pathological Conditions, Signs and Symptoms (98) · Pathologic Processes (55) · Signs and Symptoms (36) · Disease Attributes (34) · Nose Diseases (34) · Otorhinolaryngologic Diseases (34) · Chronic Disease (31)
Albuterol (29) · Formoterol Fumarate (29) · montelukast (29) · Fluticasone (28) · Budesonide (16) · Beclomethasone (15) · Mometasone Furoate (12) · Omalizumab (12) · fluticasone furoate (11) · Salmeterol Xinafoate (10) · indacaterol (10) · Fluticasone-Salmeterol Drug Combination (9) · Tiotropium Bromide (9) · Saline Solution (8) · Cholecalciferol (7)
GlaxoSmithKline (59) · Novartis Pharmaceuticals (37) · AstraZeneca (33) · Boehringer Ingelheim (26) · Chiesi Farmaceutici S.p.A. (24) · MedImmune LLC (12) · Sanofi (11) · Amphastar Pharmaceuticals, Inc. (10) · Genentech, Inc. (10) · Novartis (10) · Teva Branded Pharmaceutical Products R&D, Inc. (10) · Merck Sharp & Dohme LLC (9) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Pfizer (9) · Hoffmann-La Roche (7)
United States (331) · Germany (127) · United Kingdom (125) · Canada (100) · Poland (91) · Bulgaria (51) · Hungary (51) · Argentina (48) · Russia (46) · France (45) · South Africa (45) · South Korea (40) · Ukraine (38) · Spain (37) · China (36)
Dave Singh, MD (8) · Fernando Holguin, MD, MPH (4) · Paul O'Byrne, MD (4)
PMID 27881132, PMID 39393433, PMID 36472162, PMID 21356110, PMID 24010736, PMID 24184147, PMID 25445859, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28639856, PMID 28758192, PMID 33217063, PMID 33305842, PMID 34089147, PMID 36253275, PMID 11398072, PMID 16164444, PMID 17950857, PMID 18244953, PMID 18403223, PMID 18595980, PMID 18699936, PMID 18787222, PMID 19136369, PMID 19196814, PMID 19264687, PMID 19614621, PMID 19656525, PMID 19728196, PMID 19748656, PMID 19821718, PMID 20001651, PMID 20012982, PMID 20056900, PMID 20100026, PMID 20110554, PMID 20193079, PMID 20334686, PMID 20528605, PMID 20545703, PMID 20920778, PMID 21057005, PMID 21060320, PMID 21093024, PMID 21109557, PMID 21473764, PMID 21545249, PMID 21584948, PMID 21614939
2009 (16), 2014 (8), 2008 (6), 2015 (6), 2016 (5), 2025 (5), 2017 (4), 2018 (4), 2023 (4), 2019 (3), P01HL158507 (3), R01HL135235 (3), 2004 (1), KL2TR002346 (1), P01AT002647 (1)